Advanced stage mucinous epithelial ovarian cancer: The Hellenic Cooperative Oncology Group experience

Greenlee, 2001, Cancer statistics, 2001, CA Cancer J. Clin., 51, 15, 10.3322/canjclin.51.1.15 Balvert-Locht, 1991, Improved prognosis of ovarian cancer in the Netherlands during the period 1975–1985: a registry-based study, Gynecol. Oncol., 42, 3, 10.1016/0090-8258(91)90222-Q Einhorn, 1985, Factors influencing survival in carcinoma of the ovary. Study from a well-defined Swedish population, Cancer, 55, 2019, 10.1002/1097-0142(19850501)55:9<2019::AID-CNCR2820550932>3.0.CO;2-2 Swenerton, 1985, Ovarian carcinoma: a multivariate analysis of prognostic factors, Obstet. Gynecol., 65, 264 Boente, 1997, Gynecologic cancers, Cancer Chemother. Biol. Response Modif., 17, 536 McGuire, 2002, Survival among U.S. women with invasive epithelial ovarian cancer, Gynecol. Oncol., 84, 399, 10.1006/gyno.2001.6536 McGuire, 1996, Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer, N. Engl. J. Med., 334, 1, 10.1056/NEJM199601043340101 Piccart, 2000, Randomized intergroup trial of cisplatin–paclitaxel versus cisplatin–cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results, J. Natl. Cancer Inst., 92, 699, 10.1093/jnci/92.9.699 Muggia, 2000, Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study, J. Clin. Oncol., 18, 106, 10.1200/JCO.2000.18.1.106 Neijt, 2000, Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer, J. Clin. Oncol., 18, 3084, 10.1200/JCO.2000.18.17.3084 2002, Paclitaxel plus carboplatin versus standard chemotherapy with single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial, Lancet, 360, 505, 10.1016/S0140-6736(02)09738-6 Hess, 2004, Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment, J. Clin. Oncol., 22, 1040, 10.1200/JCO.2004.08.078 Enomoto, 2003, Is clear cell carcinoma and mucinous carcinoma of the ovary sensitive to combination chemotherapy with paclitaxel and carboplatin?, Proc.-Am. Soc. Clin. Oncol., 22, 44 Shimizu, 1998, Cytotoxic agents active against mucinous adenocarcinoma of the ovary, Oncol. Rep., 5, 99 Shimizu, 1998, A phase II study of combined CPT-11 and mitomycin-C in platinum refractory clear cell and mucinous ovarian carcinoma, Ann. Acad. Med. Singapore, 27, 650 World Health Organization, 1979 Agresti, 1990 Kaplan, 1958, Nonparametric estimation from incomplete observations, J. Am. Stat. Assoc., 53, 457, 10.2307/2281868 Cox, 1972, Regression models and life tables (with discussion), J. R. Stat. Soc., B, 34, 187 Goff, 1996, Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease, Gynecol. Oncol., 60, 412, 10.1006/gyno.1996.0065 Kikkawa, 1996, Mucinous carcinoma of the ovary. Clinicopathologic analysis, Oncology, 53, 303, 10.1159/000227577 Nomura, 2000, Noninvasive, microinvasive, and invasive mucinous carcinomas of the ovary: a clinicopathologic analysis of 40 cases, Cancer, 89, 1541, 10.1002/1097-0142(20001001)89:7<1541::AID-CNCR18>3.0.CO;2-9 Hoskins, 1992, The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study, Gynecol. Oncol., 47, 159, 10.1016/0090-8258(92)90100-W Andrews, 1988, cis-Diamminedichloroplatinum (II) accumulation in sensitive and resistant human ovarian carcinoma cells, Cancer Res., 48, 68 Kasahara, 1991, Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin, Cancer Res., 51, 3237 Kigawa, 1998, Gamma-glutamyl cysteine synthetase up-regulates glutathione and multidrug resistance-associated protein in patients with chemoresistant epithelial ovarian cancer, Clin. Cancer Res., 4, 1737 Johnson, 1999, Antagonistic interplay between antimitotic and G1-S arresting agents observed in experimental combination therapy, Clin. Cancer Res., 5, 2559 Gerhardt, 1991, Characterization of in vitro chemosensitivity of perioperative human ovarian malignancies by adenosine triphosphate chemosensitivity assay, Am. J. Obstet. Gynecol., 165, 245, 10.1016/0002-9378(91)90075-3 Pectasides, 2004, Oxaliplatin plus high dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant, taxane-pretreated: ovarian cancer. A phase II study, Gynecol. Oncol., 95, 165, 10.1016/j.ygyno.2004.06.029 Fujita, 2003, Genetic alterations in ovarian carcinoma: with specific reference to histological subtypes, Mol. Cell. Endocrinol., 202, 97, 10.1016/S0303-7207(03)00069-8 Pieretti, 2002, Heterogeneity of ovarian cancer: relationships among histological group, stage of disease, tumor markers, patient characteristics, and survival, Cancer Invest., 20, 11, 10.1081/CNV-120000361